Here are 1-2 brief analogies for MediciNova:

• Like an early-stage Biogen, focused on developing novel treatments for neurological and other serious diseases.
• A developing Amgen, building a pipeline of experimental drugs for diverse challenging conditions.

• MN-166 (ibudilast): An oral anti-inflammatory and neuroprotective agent for treating neurological disorders and substance dependence and addiction.
• MN-221 (bedoradrine): A selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma.
• MN-001 (tipelukast): An orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis.
• MN-029 (denibulin): A tubulin binding agent for treating solid tumor cancers.

Major Customers of MediciNova (MNOV)

MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics. As such, its primary "customers" are other pharmaceutical companies with whom it enters into collaboration agreements for the development, licensing, and potential commercialization of its drug candidates. Based on the provided background, MediciNova's major partners/potential customers include:

• Kissei Pharmaceutical Co., Ltd. (Symbol: 4547.T - Tokyo Stock Exchange)
• Kyorin Pharmaceutical Co., Ltd (Symbol: 4564.T - Tokyo Stock Exchange)
• Angiogene Pharmaceuticals Ltd. (Private Company)
• Meiji Seika Kaisha Ltd. (A subsidiary of Meiji Holdings Co Ltd, Symbol: 2269.T - Tokyo Stock Exchange)

• Kissei Pharmaceutical Co., Ltd. (TYO: 4547)
• Kyorin Pharmaceutical Co., Ltd. (TYO: 4564)
• Angiogene Pharmaceuticals Ltd.
• Meiji Seika Kaisha Ltd. (TYO: 2269 for parent Meiji Holdings Co., Ltd.)

Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer, and Founder

Dr. Iwaki co-founded MediciNova in September 2000 and has served as its CEO since March 2006. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery, and Pathology, and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Prior to that, he held professorships at the University of Pittsburgh School of Medicine. Dr. Iwaki has advised pharmaceutical companies and venture capital funds on research and investment strategies for over 30 years and is a board member of several biotechnology companies, including Avigen, Inc.

Jason Kruger Chief Financial Officer

Mr. Kruger has served as Chief Financial Officer of MediciNova since June 2022. He is the president and founder of Signature Analytics, an accounting services firm he established in September 2008, which was acquired by Citrin Cooperman Advisors LLC in November 2024. Before founding Signature Analytics, Mr. Kruger was a Senior Manager for Deloitte & Touche LLP from 2003 to 2008 and a Senior Accountant for Moss Adams LLP from 1999 to 2003.

Kazuko Matsuda, M.D., Ph.D, MPH Chief Medical Officer

Dr. Matsuda has served as Chief Medical Officer for MediciNova since 2010, and previously as Vice President of Clinical Development. She is responsible for all clinical development. Prior to joining MediciNova, Dr. Matsuda was a clinical advisor to the company for its MN-221 and MN-166 development programs, and an assistant professor at the University of Southern California, Keck School of Medicine. She is a board-certified pediatrician in both the United States and Japan.

David H. Crean, Ph.D. Chief Business Officer

Dr. Crean has served as Chief Business Officer since May 2021. He is also the President and CEO of Coast BioVentures LLC, an emerging life sciences venture fund, and a managing partner with Cardiff Advisory LLC, a strategic and financial advisory firm focused on mergers, acquisitions, and partnering transactions within the life science and healthcare sectors. Dr. Crean was previously a Managing Director for Objective Capital Partners, LLC, and is a limited partner with Mesa Verde Venture Partners, a leading life sciences venture fund.

Key Risks to MediciNova (MNOV)

MediciNova, Inc. (MNOV), a biopharmaceutical company focused on developing novel small molecule therapeutics for serious diseases, faces several significant risks inherent in the biotechnology industry. The most prominent risks relate to the unpredictable nature of drug development, the substantial capital required for research and commercialization, and the increasing competition in its target markets.

1. Clinical Trial Failure and Regulatory Approval Risk

The most significant risk to MediciNova's business is the potential for its product candidates to fail in clinical trials or to not receive regulatory approval. Biopharmaceutical development is a lengthy, costly, and uncertain process, where early positive results do not guarantee success in later-stage trials or ultimate approval by regulatory authorities such as the FDA. The company's lead assets, MN-166 (ibudilast) and MN-001 (tipelukast), as well as other candidates like MN-221 and MN-029, are subject to these inherent risks. Delays, suspensions, or terminations of clinical trials can lead to increased costs and significantly hinder or prevent regulatory approval. For example, a Phase 2b study for MN-221 in asthma exacerbations did not statistically meet its primary endpoint, resulting in a substantial drop in the company's stock price.

2. Funding and Capital Raising Risk

Another critical risk for MediciNova is the ongoing need to raise sufficient capital to fund its operations and contribute to the development of its product candidates. Developing novel therapeutics through multiple clinical phases to commercialization requires substantial financial resources. Although MediciNova has utilized a lean funding strategy involving grants and partnerships and reported a cash position in November 2025 that suggests it can sustain programs without near-term financing, the extensive and often unpredictable costs associated with drug development mean that the company may need to secure significant additional capital in the future. The ability to obtain such funding is crucial for the continued advancement of its pipeline.

3. Dependence on Lead Candidates and Market Competition

MediciNova's business prospects are highly dependent on the successful development and eventual commercialization of its lead product candidates, particularly MN-166 and MN-001. MN-166 is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). The failure of these key programs would have a severe adverse impact on the company. Furthermore, while MediciNova targets diseases with unmet medical needs, the market for such conditions can be highly competitive. The landscape for drug development in areas like ALS, for instance, is seeing accelerated activity, with a surge in early-stage clinical trials. This increasing competition from other pharmaceutical and biotechnology companies could affect the commercial viability and market share of MediciNova's products, even if approved.

MediciNova (MNOV) is developing several product candidates for various diseases. The addressable markets for their main products or services are as follows:

MN-166 (ibudilast)

• Amyotrophic Lateral Sclerosis (ALS): The addressable market for ALS treatment in the U.S. is US$987.6 million. Approximately 20,000 ALS patients are in the U.S., with around 5,000 new diagnoses annually.

MN-001 (tipelukast)

• Idiopathic Pulmonary Fibrosis (IPF): The global Idiopathic Pulmonary Fibrosis market size is expected to reach $4.7 billion by 2027. In 2023, the total market size of Idiopathic Pulmonary Fibrosis in the 7MM (United States, Germany, France, Italy, Spain, UK, and Japan) was approximately USD 3,300 million. The global Idiopathic Pulmonary Fibrosis market generated US$2,970.69 million in 2025 and is estimated to reach US$6,736.49 million by 2035, growing at a CAGR of 9.4% from 2026-2035. In the U.S., IPF affects an estimated 128,000 individuals, with approximately 48,000 new cases diagnosed each year.
• Nonalcoholic Steatohepatitis (NASH): NASH prevalence in the U.S. is 2-5%, with an additional 10-20% of Americans having "fatty liver."

MN-221 (bedoradrine)

The license agreement for MN-221 was terminated in October 2022, and therefore, it is no longer actively developed by MediciNova.

• Acute Exacerbations of Asthma: In 2010, the direct costs associated with hospital care due to asthma in the U.S. were estimated at $5.5 billion. Annual emergency department visits for asthma in the U.S. were approximately 1.75 million in 2007.

MN-029 (denibulin)

No specific addressable market size information for MN-029 (denibulin) for solid tumor cancers was found. However, it is being developed for solid tumor cancers.

MediciNova (MNOV) is a biopharmaceutical company with a pipeline of small molecule therapeutics focused on treating serious diseases. While analysts generally do not forecast significant product sales revenue for MediciNova within the next two to three years, several key pipeline advancements and strategic activities are expected to drive future revenue growth through potential partnerships, milestone payments, and eventually, product commercialization.

The primary anticipated drivers of future revenue growth for MediciNova include:

1. Positive Top-Line Results and Potential Regulatory Submission for MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS): MediciNova completed patient enrollment in its Phase 2b/3 COMBAT-ALS clinical trial for MN-166 in September 2025, with top-line results anticipated by the end of 2026. Positive outcomes from this pivotal trial are crucial and could pave the way for a regulatory submission to the U.S. Food and Drug Administration (FDA) within the 2-3 year timeframe. MN-166 has already received Fast Track and Orphan Drug designations from the FDA for ALS, which could accelerate the review process and provide market exclusivity upon approval. Any significant progress toward regulatory approval, including a successful submission, could trigger milestone payments from existing or new collaboration agreements.
2. Advancement and Potential Partnering of MN-001 (tipelukast) for Nonalcoholic Steatohepatitis (NASH): MediciNova completed patient enrollment for its Phase 2 trial of MN-001 for NASH in November 2025, with top-line data expected in the summer of 2026. MN-001 also holds Fast Track designation for NASH with fibrosis. Positive clinical data for MN-001 could significantly enhance its attractiveness for new licensing agreements or expanded partnerships, leading to upfront payments and development milestones, contributing to revenue growth.
3. New or Expanded Partnerships and Licensing Agreements for Pipeline Candidates: As a clinical-stage biopharmaceutical company, MediciNova's strategy includes building a strong product portfolio through alliances. Successful progression of its lead drug candidates, particularly MN-166 across its various indications (including progressive multiple sclerosis where it is Phase 3-ready and degenerative cervical myelopathy where it is in Phase 3), as well as MN-001, could lead to new or expanded collaboration agreements with pharmaceutical companies. These partnerships typically involve upfront payments, research and development funding, and milestone payments upon achieving specific clinical or regulatory goals, representing significant drivers of future revenue.

Share Issuance

• MediciNova entered into a Standby Equity Purchase Agreement (SEPA) in July/August 2025, allowing the company to sell up to $30 million of its common stock over a 36-month period to investment funds managed by Yorkville Advisors Global LP.
• In March 2026, MediciNova established a $50 million at-the-market (ATM) facility to support operations.
• In January 2021, MediciNova issued US$20 million in shares of its common stock to 3D Opportunity Master Fund through a private placement transaction.

Inbound Investments

• MediciNova secured a $22 million grant from the National Institutes of Health (NIH) to support its Expanded Access Program for ALS, which commenced in March 2025.
• A Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global LP, signed in July/August 2025, provides access to up to $30 million in capital over 36 months.
• In January 2021, the company received a US$20 million investment from 3D Opportunity Master Fund through a private placement.

Capital Expenditures

• Total research and development (R&D) and patent spend for MediciNova remained consistent at $7.2 million in 2025, primarily directed towards advancing clinical programs for MN-166 and MN-001, including higher trial costs.
• The US$20 million raised in January 2021 was allocated to initiating a new clinical trial of MN-166 for glioblastoma, developing an intravenous formulation of MN-166 for ALS, and commencing a Phase 2 clinical trial of MN-001 in nonalcoholic steatohepatitis (NASH).
• MediciNova's projected operating needs for 2026 are approximately $16.2 million, which includes funding for ongoing development programs.